Top 20 Companies in the Global Cardiac Resynchronisation Therapy Market (2025-2035): Expert View by Spherical Insights
RELEASE DATE: Apr 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The rising incidence of heart failure cases serves as a primary reason that drives the need for CRT. Worldwide, millions of individuals experience reduced ejection fraction and ventricular desynchrony, which deteriorate their heart function and increase their risk of death. The function of CRT restoration enables normal heart rhythms, which results in better cardiac performance and decreased hospital needs, while maintaining patient well-being. Another factor that drives the demand for CRT is the growing number of elderly individuals. Older individuals are highly likely to be affected by cardiovascular diseases, such as heart failure, meaning that there will be an increase in the patient base for CRT treatment. The last factor that drives market growth is the technological advancements in cardiac implantation devices. Today, the CRT devices have long-lasting batteries, remote monitoring capability, better lead placement techniques, and adaptive pacing.
Heart failure stands as the primary clinical result of cardiovascular diseases, which affect approximately 26 million individuals throughout the world, according to worldwide epidemiological data.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cardiac Resynchronisation Therapy Market
Cardiac Resynchronisation Therapy Market Size & Statistics
- The Market Size for Cardiac Resynchronization Therapy Was Estimated to be worth USD 6.76 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 5.6% between 2025 and 2035.
- The Cardiac Resynchronisation Therapy Market Size is anticipated to reach USD 12.30 Billion by 2035.
- North America is estimated to dominate the market during the forecast period in the Cardiac Resynchronisation Therapy Market.
- Asia-Pacific is projected to grow the fastest during the forecast period in the Cardiac Resynchronisation Therapy Market.
Market Segmentation
Cardiac Resynchronisation Therapy Market Size, Share, By Product Type (CRT-Defibrillator, CRT-Pacemaker), By End Use (Hospitals, Cardiac Centres, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035.
Regional growth and demand
North America is expected to dominate the market during the forecast period in the cardiac resynchronisation therapy market.
North America held the majority of the market share by revenue for the cardiac resynchronisation therapy market. The dominance in these markets can be attributed to the sophisticated health care infrastructure, the increased awareness regarding heart treatments, the availability of insurance policies, and the use of implantable cardiac devices. The presence of key medical device companies and favourable regulations in these nations contributes to the strength of the regional market.
It is estimated that no less than 6.7 million Americans aged 20 years or older are afflicted with congestive heart failure. The systematic literature review reported that U.S. heart failure hospitalisation costs averaged between USD 7,094 and USD 9,769 for median expenses, while the mean costs ranged from approximately USD 10,737 to USD 17,830 based on different patient groups and their disease severity levels.
Asia-Pacific is projected to grow the fastest during the forecast period in the cardiac resynchronisation therapy market.
Asia-Pacific is projected to grow the fastest during the forecast period in the cardiac resynchronisation therapy market. The rising prevalence of cardiovascular diseases, together with the increasing geriatric population, better healthcare access, and the broader reimbursement policies that various countries implement, including China, India, Japan, and South Korea. The region experiences a strong compound annual growth rate because of its rapid urbanisation and its people learning about advanced cardiac therapies and their growing use of current medical technology.
More than 4.25 million deaths from cardiovascular diseases occurred in 2021, according to the WHO, and almost half (49.2%) of these happened prematurely in the age range 30-69 in the South Asian region.
Ready to lead the Cardiac Resynchronisation Therapy Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Cardiac Resynchronisation Therapy Market
- Rising Prevalence of Heart Failure Globally
- Growing Geriatric Population
- Technological Advancements in CRT Devices
- Increased Adoption of Remote Monitoring and Telehealth
- Expansion Of Minimally Invasive and Leadless CRT Systems
- Rising Healthcare Expenditure and Reimbursement Coverage
- Increasing Awareness and Early Diagnosis of Heart Conditions
- Shift Toward Personalised and Adaptive Pacing Algorithms
- Growth In Emerging Markets (Asia‑Pacific, Latin America)
- Strategic Partnerships and Acquisitions Among Device Manufacturers
- Rising Prevalence of Heart Failure Globally
The worldwide rise of heart failure patients has become the main reason for hospitals to start using CRT treatment. CRT devices function as vital tools that doctors use to treat patients with heart failure who experience reduced ejection fraction and ventricular desynchrony through the restoration of their heart rhythms, which results in better life quality and decreased need for hospitalisation. The trend ensures more patients will become eligible for CRT treatments, which will increase their need for treatment.
- Growing Geriatric Population
The rising number of elderly people in North America, Europe and Asian regions leads to more cases of heart disease. The need for CRT devices to treat advanced heart failure and preserve heart function has grown because older adults develop chronic heart conditions at higher rates.
- Technological Advancements in CRT Devices
The development of battery technology, lead placement methods, and adaptive pacing systems has led to safer and more effective CRT devices. The new technologies improve patient results while decreasing health risks, which leads doctors and patients to use them more frequently.
- Increased Adoption of Remote Monitoring and Telehealth
Current CRT technology enables remote heart function monitoring through its connection to telemonitoring systems, which doctors can use to observe patients. The trend delivers three benefits because it improves patient safety and decreases hospital visits, and it enhances long-term therapy management for patients who live in areas with insufficient access to specialised cardiac treatment.
- Expansion Of Minimally Invasive and Leadless CRT Systems
The surgical hazards decrease, and recovery periods decrease while patient comfort increases through the use of leadless CRT systems, which require fewer invasive procedures. The demand for less invasive treatment methods from hospitals and patients drives the development of new technologies, which increase the market availability of CRT devices.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cardiac Resynchronisation Therapy Market
Empower your strategic planning
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the anti-venom market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 20 Companies Leading the Cardiac Resynchronisation Therapy Market
- Abbott Laboratories
- Medtronic plc
- Boston Scientific Corporation
- BIOTRONIK SE & Co. KG
- MicroPort Scientific Corporation
- LivaNova PLC
- Lepu Medical Technology (Beijing) Co., Ltd.
- OSYPKA Medical GmbH
- MEDICO S.p.A.
- Schiller AG
- OSCOR Inc.
- Nihon Kohden Corporation
- Koninklijke Philips N.V.
- Japan Lifeline Co., Ltd.
- Integer Holdings Corporation
- Shree Pacetronix Ltd.
- EBR Systems, Inc.
- Cardiac Dimensions, Inc.
- Cook Medical, Inc.
- AngioDynamics, Inc.
1. Medtronic plc
Headquarters: Dublin, Ireland.
The company was started in 1949, and its recent revenue was USD 32 billion in 2024, and moreover, its Global Operating Sites are in North America, Europe, Asia and other international markets. Its Product Portfolio consists of Cardiac resynchronisation therapy devices, pacemakers, defibrillators and cardiovascular devices. It is one of the global leaders in medical technology. Strong presence in cardiac care and implantable device markets.
2. Abbott Laboratories
Headquarters: Illinois, USA.
The company was started in the year 1888, and its recent revenue was USD 40 billion in the year 2024, and moreover, its Global Operating Sites are in North America, Europe, Asia and other global markets. Its Product Portfolio consists of Cardiac resynchronisation therapy devices, diagnostic equipment, medical devices and pharmaceuticals. It is known for advanced cardiovascular solutions. Strong presence in global healthcare markets.
3. Boston Scientific Corporation
Headquarters: Massachusetts, USA.
The company was started in 1979, and its recent revenue was USD 14 billion in the year 2024, and moreover, its Global Operating Sites are in North America, Europe, Asia and other international markets. Its Product Portfolio consists of Cardiac resynchronisation therapy devices, interventional cardiology products and medical devices. It is one of the major players in cardiovascular technology. Strong presence in minimally invasive treatments.
4. Biotronik SE & Co. KG
Headquarters: Berlin, Germany.
The company was started in 1963, and its recent revenue was USD 1.5 billion in 2024, and moreover, its Global Operating Sites are in Europe, North America, Asia and other international markets. Its Product Portfolio consists of Cardiac resynchronisation therapy devices, pacemakers and implantable cardiac devices. It is known for innovative cardiac rhythm management solutions. Strong presence in European and global cardiac device markets.
5. MicroPort Scientific Corporation
Headquarters: Shanghai, China.
The company was started in the year 1998, and its recent revenue was USD 1.2 billion in the year 2024, and moreover, its Global Operating Sites are in China, Europe, North America and Asia. Its Product Portfolio consists of Cardiac resynchronisation therapy devices, stents and cardiovascular medical devices. It is one of the emerging global medical device companies. Strong presence in cardiovascular treatment markets.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cardiac Resynchronisation Therapy Market
Are you ready to discover more about the Cardiac Resynchronisation Therapy Market?
The report provides an in-depth analysis of the leading companies operating in the global cardiac resynchronisation therapy market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes:
Company Profile
- Abbot Laboratories.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Medtronic plc
- Boston Scientific Corporation
- BIOTRONIK SE & Co. KG
- MicroPort Scientific Corporation
- LivaNova PLC
- Lepu Medical Technology (Beijing) Co., Ltd.
- OSYPKA Medical GmbH
- MEDICO S.p.A.
- Schiller AG
- OSCOR Inc.
- Nihon Kohden Corporation
- Koninklijke Philips N.V.
- Japan Lifeline Co., Ltd.
- Integer Holdings Corporation
- Shree Pacetronix Ltd.
- EBR Systems, Inc.
- Cardiac Dimensions, Inc.
- Cook Medical, Inc.
- AngioDynamics, Inc.
Conclusion
Global market expansion is fuelled by increasing incidences of heart failure, rising geriatric population, awareness of advanced cardiac therapies, and high technological advancements in implantable cardiac devices. North America is expected to dominate the market during the forecast period due to the sophisticated health care infrastructure, the increased awareness regarding heart treatments, and the availability of insurance. Asia-Pacific is projected to grow the fastest during the forecast period due to the rising prevalence of cardiovascular diseases, together with the increasing geriatric population and better healthcare access.
Our Top Reports
Construction Punch List Software Market Size, Growth 2035
China Foodservice Market Size and Growth
Europe LPG Market Size, Shares, Trends to 2035
United Kingdom Swine Vaccines Market Forecasts to 2035
Global Vitamin C Market Size, Growth, Forecast 2035
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Cardiac Resynchronisation Therapy Market
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?